Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 781 to 786 of 786 entries
Sorted by: Best Match Show Resources per page
Fasted Intestinal Solubility Limits and Distributions Applied to the Biopharmaceutics and Developability Classification Systems.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

Abuhassan Q, Khadra I, Pyper K, Augustijns P, Brouwers J, Halbert GW.
PMID: 34923138
Eur J Pharm Biopharm. 2021 Dec 16; doi: 10.1016/j.ejpb.2021.12.006. Epub 2021 Dec 16.

After oral administration, a drug's solubility in intestinal fluid is an important parameter influencing bioavailability and if the value is known it can be applied to estimate multiple biopharmaceutical parameters including the solubility limited absorbable dose. Current in vitro...

Cite
Abuhassan Q, Khadra I, Pyper K, et al. Fasted Intestinal Solubility Limits and Distributions Applied to the Biopharmaceutics and Developability Classification Systems. Eur J Pharm Biopharm. 2021;doi: 10.1016/j.ejpb.2021.12.006.
Abuhassan, Q., Khadra, I., Pyper, K., Augustijns, P., Brouwers, J., & Halbert, G. W. (2021). Fasted Intestinal Solubility Limits and Distributions Applied to the Biopharmaceutics and Developability Classification Systems. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, . https://doi.org/10.1016/j.ejpb.2021.12.006
Abuhassan, Qamar, et al. "Fasted Intestinal Solubility Limits and Distributions Applied to the Biopharmaceutics and Developability Classification Systems." European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V vol. (2021). doi: https://doi.org/10.1016/j.ejpb.2021.12.006
Abuhassan Q, Khadra I, Pyper K, Augustijns P, Brouwers J, Halbert GW. Fasted Intestinal Solubility Limits and Distributions Applied to the Biopharmaceutics and Developability Classification Systems. Eur J Pharm Biopharm. 2021 Dec 16; doi: 10.1016/j.ejpb.2021.12.006. Epub 2021 Dec 16. PMID: 34923138.
Copy Download .nbib Format: NLM
Availability of Emergency Drugs and Essential Equipment in Intensive Care Units in Hospitals of Ethiopia: A Multicenter Cross-Sectional Study.

Open access emergency medicine : OAEM

Hunie M, Desse T, Fenta E, Teshome D, Gelaw M, Gashaw A.
PMID: 33293877
Open Access Emerg Med. 2020 Dec 01;12:435-440. doi: 10.2147/OAEM.S285695. eCollection 2020.

PURPOSE: Emergency drugs and essential equipment are important to successfully manage patients in the intensive care unit (ICUs). The absence of these emergency drugs and essential equipment might result in mortality and morbidity which is more compounded in resource-limited...

Cite
Hunie M, Desse T, Fenta E, et al. Availability of Emergency Drugs and Essential Equipment in Intensive Care Units in Hospitals of Ethiopia: A Multicenter Cross-Sectional Study. Open Access Emerg Med. 2020;12:435-440doi: 10.2147/OAEM.S285695.
Hunie, M., Desse, T., Fenta, E., Teshome, D., Gelaw, M., & Gashaw, A. (2020). Availability of Emergency Drugs and Essential Equipment in Intensive Care Units in Hospitals of Ethiopia: A Multicenter Cross-Sectional Study. Open access emergency medicine : OAEM, 12435-440. https://doi.org/10.2147/OAEM.S285695
Hunie, Metages, et al. "Availability of Emergency Drugs and Essential Equipment in Intensive Care Units in Hospitals of Ethiopia: A Multicenter Cross-Sectional Study." Open access emergency medicine : OAEM vol. 12 (2020): 435-440. doi: https://doi.org/10.2147/OAEM.S285695
Hunie M, Desse T, Fenta E, Teshome D, Gelaw M, Gashaw A. Availability of Emergency Drugs and Essential Equipment in Intensive Care Units in Hospitals of Ethiopia: A Multicenter Cross-Sectional Study. Open Access Emerg Med. 2020 Dec 01;12:435-440. doi: 10.2147/OAEM.S285695. eCollection 2020. PMID: 33293877; PMCID: PMC7719042.
Copy Download .nbib Format: NLM
Ion Transport Modulators as Antimycobacterial Agents.

Tuberculosis research and treatment

Mitini-Nkhoma SC, Fernando N, Ishaka GKD, Handunnetti SM, Pathirana SL.
PMID: 33294223
Tuberc Res Treat. 2020 Nov 20;2020:3767915. doi: 10.1155/2020/3767915. eCollection 2020.

There is an urgent need for better and safer therapeutic interventions for tuberculosis (TB). We assessed the effects of FDA-approved ion transport modulators, namely, ambroxol HCl, amiloride HCl, diazoxide, digoxin, furosemide, hydrochlorothiazide (HCTZ), metformin, omeprazole, pantoprazole, phenytoin, verapamil, and...

Cite
Mitini-Nkhoma SC, Fernando N, Ishaka GKD, et al. Ion Transport Modulators as Antimycobacterial Agents. Tuberc Res Treat. 2020;2020:3767915doi: 10.1155/2020/3767915.
Mitini-Nkhoma, S. C., Fernando, N., Ishaka, G. K. D., Handunnetti, S. M., & Pathirana, S. L. (2020). Ion Transport Modulators as Antimycobacterial Agents. Tuberculosis research and treatment, 20203767915. https://doi.org/10.1155/2020/3767915
Mitini-Nkhoma, Steven C, et al. "Ion Transport Modulators as Antimycobacterial Agents." Tuberculosis research and treatment vol. 2020 (2020): 3767915. doi: https://doi.org/10.1155/2020/3767915
Mitini-Nkhoma SC, Fernando N, Ishaka GKD, Handunnetti SM, Pathirana SL. Ion Transport Modulators as Antimycobacterial Agents. Tuberc Res Treat. 2020 Nov 20;2020:3767915. doi: 10.1155/2020/3767915. eCollection 2020. PMID: 33294223; PMCID: PMC7700046.
Copy Download .nbib Format: NLM
Standardizing Discharge Furosemide Duration Following Congenital Heart Surgery.

World journal for pediatric & congenital heart surgery

Trivedi M, Diaz-Castrillon CE, Morell E.
PMID: 34825593
World J Pediatr Congenit Heart Surg. 2022 Jan;13(1):16-22. doi: 10.1177/21501351211049308. Epub 2021 Nov 26.

No abstract available.

Cite
Trivedi M, Diaz-Castrillon CE, Morell E. Standardizing Discharge Furosemide Duration Following Congenital Heart Surgery. World J Pediatr Congenit Heart Surg. 2021;13(1):16-22doi: 10.1177/21501351211049308.
Trivedi, M., Diaz-Castrillon, C. E., & Morell, E. (2022). Standardizing Discharge Furosemide Duration Following Congenital Heart Surgery. World journal for pediatric & congenital heart surgery, 13(1), 16-22. https://doi.org/10.1177/21501351211049308
Trivedi, Mira, et al. "Standardizing Discharge Furosemide Duration Following Congenital Heart Surgery." World journal for pediatric & congenital heart surgery vol. 13,1 (2022): 16-22. doi: https://doi.org/10.1177/21501351211049308
Trivedi M, Diaz-Castrillon CE, Morell E. Standardizing Discharge Furosemide Duration Following Congenital Heart Surgery. World J Pediatr Congenit Heart Surg. 2022 Jan;13(1):16-22. doi: 10.1177/21501351211049308. Epub 2021 Nov 26. PMID: 34825593.
Copy Download .nbib Format: NLM
The furosemide stress test: Perspectives for acute kidney injury diagnosis.

Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia

López-Hernández FJ.
PMID: 34747433
J Bras Nefrol. 2021 Oct-Dec;43(4):452-454. doi: 10.1590/2175-8239-JBN-2021-E010.

No abstract available.

Cite
López-Hernández FJ. The furosemide stress test: Perspectives for acute kidney injury diagnosis. J Bras Nefrol. 2021;43(4):452-454doi: 10.1590/2175-8239-JBN-2021-E010.
López-Hernández, F. J. (2021). The furosemide stress test: Perspectives for acute kidney injury diagnosis. Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia, 43(4), 452-454. https://doi.org/10.1590/2175-8239-JBN-2021-E010
López-Hernández, Francisco J. "The furosemide stress test: Perspectives for acute kidney injury diagnosis." Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia vol. 43,4 (2021): 452-454. doi: https://doi.org/10.1590/2175-8239-JBN-2021-E010
López-Hernández FJ. The furosemide stress test: Perspectives for acute kidney injury diagnosis. J Bras Nefrol. 2021 Oct-Dec;43(4):452-454. doi: 10.1590/2175-8239-JBN-2021-E010. Portuguese. PMID: 34747433.
Copy Download .nbib Format: NLM
Nalfurafine, a G-Protein-Biased KOR (Kappa Opioid Receptor) Agonist, Enhances the Diuretic Response and Limits Electrolyte Losses to Standard-of-Care Diuretics.

Hypertension (Dallas, Tex. : 1979)

Meariman JK, Sutphen JC, Gao J, Kapusta DR.
PMID: 34852633
Hypertension. 2022 Feb;79(2):379-390. doi: 10.1161/HYPERTENSIONAHA.121.18503. Epub 2021 Dec 02.

Nalfurafine is a G-protein-biased KOR (kappa opioid receptor) agonist that produces analgesia and lacks central nervous system adverse effects. Here, we examined the cardiovascular and renal responses to intravenous and oral nalfurafine alone and in combination with furosemide, hydrochlorothiazide,...

Cite
Meariman JK, Sutphen JC, Gao J, et al. Nalfurafine, a G-Protein-Biased KOR (Kappa Opioid Receptor) Agonist, Enhances the Diuretic Response and Limits Electrolyte Losses to Standard-of-Care Diuretics. Hypertension. 2021;79(2):379-390doi: 10.1161/HYPERTENSIONAHA.121.18503.
Meariman, J. K., Sutphen, J. C., Gao, J., & Kapusta, D. R. (2022). Nalfurafine, a G-Protein-Biased KOR (Kappa Opioid Receptor) Agonist, Enhances the Diuretic Response and Limits Electrolyte Losses to Standard-of-Care Diuretics. Hypertension (Dallas, Tex. : 1979), 79(2), 379-390. https://doi.org/10.1161/HYPERTENSIONAHA.121.18503
Meariman, Jacob K, et al. "Nalfurafine, a G-Protein-Biased KOR (Kappa Opioid Receptor) Agonist, Enhances the Diuretic Response and Limits Electrolyte Losses to Standard-of-Care Diuretics." Hypertension (Dallas, Tex. : 1979) vol. 79,2 (2022): 379-390. doi: https://doi.org/10.1161/HYPERTENSIONAHA.121.18503
Meariman JK, Sutphen JC, Gao J, Kapusta DR. Nalfurafine, a G-Protein-Biased KOR (Kappa Opioid Receptor) Agonist, Enhances the Diuretic Response and Limits Electrolyte Losses to Standard-of-Care Diuretics. Hypertension. 2022 Feb;79(2):379-390. doi: 10.1161/HYPERTENSIONAHA.121.18503. Epub 2021 Dec 02. PMID: 34852633; PMCID: PMC8755620.
Copy Download .nbib Format: NLM
Showing 781 to 786 of 786 entries